Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, gastrointestinal and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG , a world leader in offering medicines to protect health, treat disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. Novartis is the only company with leadership positions in both patented and generic pharmaceuticals. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. In 2006, the Group's businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 101,000 associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

* Known as Gl
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 /PRNewswire/ ... industry. Because of its leading role in educating thought ... the functions that can heavily influence how well a ... to a new study from research and consulting leader ... Medical Affairs leaders need to focus on are early ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... Progress in Advancing Second-Generation ... CCR9 Drug towards ... announced the completion of enrollment of 436 patients in the,company,s ... a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in patients with ...
... DIEGO, June 12 Vical Incorporated,(Nasdaq: VICL ... of cash payments,and equity investments from AnGes MG, ... funding of the company,s ongoing,Allovectin-7(R) Phase 3 metastatic ... equity investments, Vical has received $15.3 million to ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4
(Date:7/3/2015)... ... ... Harvest Hope Food Bank will hopefully be getting a large donation of canned ... area of Greenville SC are making it their mission to collect as many canned items ... for donations from the public as well. As part of the canned food drive, these ...
(Date:7/3/2015)... ... 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 (a ... Westin Galleria Dallas. , Designed to take participants from the basic training and fundamentals ...
(Date:7/3/2015)... ... 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce the ... Center website. Just as the previous version did, the new website will serve as ... and ovarian cancer warning information. The site is routinely updated with news articles on ...
(Date:7/3/2015)... Red Deer, Alberta (PRWEB) , ... July 03, 2015 , ... ... Camp host their 24-Hour Train-a-Thon where they provide members of the Red Deer community ... This year’s full day of fitness training, games, food, events and entertainment raised thousands ...
(Date:7/2/2015)... ... , ... Following the recent report by JAMA Internal Medicine published ... Americans, Samir Becic emphatically declared a war on obesity in the United States. , ... "We must understand the magnitude of this discovery. For that reason, I am declaring, ...
Breaking Medicine News(10 mins):Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 2Health News:Greenville Area AlignLife Offices to do a Thanksgiving in July Food Drive 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4
... by researchers at the University of California, San ... pressure, is a predictor of mortality among breast ... that hypertension accounts for approximately 30 percent of ... cancer patients. , According to the study,s lead ...
... confusing blend of hearing correctly at normal volumes, but without understanding the consonants ... that must be used to address this type of hearing loss. , ... (PRWEB) March ... be the solution for hearing loss. But according to Mr. Randy Wohlers, ...
... CDs, DVDs, Scripts and Exclusive Tickets to Go ... DVDs, scripts and exclusive tickets will be auctioned ... Association of People with Disabilities (AAPD), the country,s ... a Change" is being held in conjunction with ...
... /PRNewswire-FirstCall/ - CRH Medical Corporation (CRM:TSX-V) announced today that ... positive in 2009. , The steps include negotiating an ... in the Centers will be a variable cost to ... the number of patients the doctor sees. This will ...
... Anna Kournikova has just returned from her first ... combined effects of years of poverty, violence and ... population. (Photo: http://www.newscom.com/cgi-bin/prnh/20090304/DC78519 )"It ... all," said Kournikova, following her visit. "This ...
... of Postal Bill on Capitol HillALEXANDRIA, Va., March ... the 76th Co-Sponsor of H.R. 22, a bill ... obligation. The bill, originally sponsored by Congressmen ... presently before the Oversight and Government Reform Committee ...
Cached Medicine News:Health News:High blood pressure linked to earlier death among African-American breast cancer patients 2Health News:High blood pressure linked to earlier death among African-American breast cancer patients 3Health News:All Hearing Aids Are not Created Equal According To MyHearPod.com Founder 2Health News:All Hearing Aids Are not Created Equal According To MyHearPod.com Founder 3Health News:Celebrity Memorabilia Auction to Benefit AAPD 2Health News:CRH Medical focuses on profitability in 2009 2Health News:PSI Brings Tennis Star Anna Kournikova to Haiti Bringing Hope and Assistance to Child Slaves 2Health News:PSI Brings Tennis Star Anna Kournikova to Haiti Bringing Hope and Assistance to Child Slaves 3Health News:Congressman Jerry McNearney (D-Calif.) becomes 76th Co-Sponsor of H.R. 22 2
... Used for stone manipulation ... urinary tract. Enhanced wire ... dilation in the ureter. ... easy, ergonomic one-handed operation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used to provide drainage following open ... are employed to provide enhanced drainage ... provides maximum softness for enhanced patient ... to latex catheters. Supplied sterile in ...
... Reflotron Plus Chemistry Analyzer is an in ... determination of clinical chemistry parameters using Reflotron Test ... photometry and ensures rapid and reliable results while ... a clear LC display and the profile can ...
Medicine Products: